CKD Bio is pursuing China National Medical Products Administration (NMPA) approval for its botulinum toxin product, targeting a 2027 market entry. The Seoul-based manufacturer has been building international presence beyond its home market, where it competes against AbbVie's Botox and Galderma's Dysport in the neuromodulator space.
Regulatory
CKD Bio Pursues China Botox Approval—2027 Launch Targeted
South Korean toxin maker seeks regulatory path into world's second-largest aesthetic market.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
2027 launch targeted for China market entry.
China's aesthetic market has grown into a critical battleground for toxin makers. Local players like Lanzhou Institute of Biological Products dominate on price, but multinational approval carries prestige and pricing power—particularly among tier-one city practitioners who value international-grade products and regulatory pedigree. CKD Bio's timeline suggests NMPA review is underway; approval would mark the company's first major Asian regulatory win outside South Korea and Japan.
Source: original report ↗
Frequently asked questions
When will CKD Bio's botulinum toxin be available in China?
CKD Bio is targeting a 2027 market entry in China pending NMPA approval. The Seoul-based manufacturer is currently pursuing regulatory clearance from China's National Medical Products Administration, which would represent its first major regulatory win outside South Korea and Japan.
Who are the main competitors in China's botulinum toxin market?
Local players like Lanzhou Institute of Biological Products dominate on price, while multinational brands like AbbVie's Botox and Galderma's Dysport compete on prestige and regulatory pedigree. International-grade products command premium pricing, especially among tier-one city practitioners.
Why is China's aesthetic market important for toxin manufacturers?
China's aesthetic market has become a critical battleground for botulinum toxin makers due to its size as the world's second-largest aesthetic market. Multinational approval carries significant prestige and pricing power, particularly among high-end practitioners in major cities who prioritize international-grade products and regulatory credentials.
What is CKD Bio's current market presence?
CKD Bio is a Seoul-based botulinum toxin manufacturer that currently competes in South Korea and Japan. The company is building international presence and pursuing expansion into China as part of its strategy to compete against major players like AbbVie and Galderma.
How does NMPA approval affect pricing for botulinum toxin in China?
NMPA-approved multinational products can command premium pricing compared to local alternatives, particularly among tier-one city practitioners who value international regulatory pedigree. International-grade status provides pricing power that local competitors like Lanzhou Institute of Biological Products cannot match.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.